Eli Lilly: Teriparatide sales are expected to exceed $36.5 billion in 2025, with a 2026 performance forecast of $80 billion to $83 billion.

2026-02-20 20:03:20

Recently, Eli Lilly released its full-year 2025 financial report, with global revenue reaching $19.292 billion, a 43% increase compared to the same period in 2024 ($13.533 billion). The main drivers are the sales growth of Mounjaro (Tirzepatide, for diabetes/obesity indications) and Zepbound (Tirzepatide, for obesity indications).

According to GAAP, the company’s net profit was $6.636 billion (up 50% year-over-year), with earnings per share (EPS) of $7.39 (up 51% year-over-year), both including $0.52 per share in acquisition research and development (IPR&D) expenses. On a non-GAAP basis, net profit was $6.771 billion (up 41% year-over-year), with EPS of $7.54 (up 42% year-over-year), also including $0.52 per share in IPR&D expenses.

The company also issued guidance for 2026, with expected revenue of $80 billion to $83 billion and non-GAAP EPS of $33.50 to $35.00.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes